Araştırma Makalesi
BibTex RIS Kaynak Göster

Yıl 2021, Cilt: 5 Sayı: 1, 77 - 82, 30.06.2021

Namık Kılınç

https://doi.org/10.32571/ijct.944049
Cited By: 3

Öz

Destekleyen Kurum

Iğdır Üniversitesi

Proje Numarası

2020-SBE-A03

Teşekkür

Projeye verdikleri destekten dolayı Iğdır Üniversitesi Bilimsel Araştırma Projeleri birimine teşekkür ederim.

Kaynakça

  • El-Kabbani, O.; Ruiz, F.; Darmanin, C.; Chung, R. T. Cell Mol Life Sci. 2004, 61(7), 750-762.
  • Brownlee, M. Nature. 2001, 414(6865), 813-820.
  • Nishimura, C.; Yamaoka, T.; Mizutani, M.; Yamashita, K.; Akera, T.; Tanimoto, T. Biochim. Biophys. Acta. 1991, 1078(2), 171-178.
  • Hotta, N.; Kawamori, R.; Fukuda, M.; Shigeta, Y. Diabet. Med. 2012, 29(12), 1529-1533.
  • Ramana, K.V.; Srivastava, S.K. Cytokine. 2006, 36, 115-122.
  • Ramasamy, R.; Liu, H.; Oates, P.J.; Schaefer, S. Cardiovasc. Res. 1999, 42, 130-139.
  • Hwang, Y.C.; Sato, S.; Tsai, J.Y.; Yan, S.; Bakr, S.; Zhang, H.; Ramasamy, R. FASEB J. 2002, 16, 243-245.
  • Berry, G.T. Eur. J. Pediatr. 1995, 154, 53-64.
  • Lee, K.W.; Ko, B.C.; Jiang, Z.; Cao, D.; Chung, S.S. Anti-cancer drugs. 2001, 12, 129-132.
  • Regenold, W.T.; Kling, M.A.; Hauser, P. Psychoneuroendocrinology. 2000, 25, 593-606.
  • Regenold, W.T.; Phatak, P.; Kling, M.A.; Hauser, P. Mol. Psychiatry. 2004, 9, 731.
  • Saraswat, M.; Mrudula, T.; Kumar, P.U.; Suneetha, A.; Rao, T.S.; Srinivasulu, M.; Reddy, G.B. Med. Sci. Monit. 2006, 12, 525-529.
  • Ramana, K.V.; Bhatnagar, A.; Srivastava, S.K. FASEB J 2004, 18, 1209–1218.
  • Chandra, D.; Ramana, K.V.; Friedrich, B.; Srivastava, S.; Bhatnagar, A.; Srivastava, S.K. Chem. Biol. Interact. 2003, 143–144, 605–612.
  • Cerelli, K.J.; Curtis, D.L.; Dunn, J.P.; Nelson, P.H.; Peak, T.M.; Waterbury, L.D. J. Med. Chem. 1986, 29, 2347-2351.
  • Schrödinger Release 2020-3: Schrödinger, 2020, LLC, New York, NY.
  • Sastry, G.M.; Adzhigirey, M.; Day, T.; Annabhimoju, R.; Sherman, W. J. Comput. Aided Mol. Des. 2013, 27, 221-234.
  • Friesner, R.A.; Banks, J.L.; Murphy, R.B.; Halgren, T.A.; Klicic, J.J.; Mainz, D.T.; Shenkin, P.S. J. Med. Chem. 2004, 47, 1739-1749.
  • Halgren, T.A.; Murphy, R.B.; Friesner, R.A.; Beard, H.S.; Frye, L.L.; Pollard, W.T.; Banks, J.L. J. Med. Chem. 2004, 47, 1750-1759.
  • Genheden, S.; Ryde, U. Expert. Opin. Drug. Discov. 2015, 10(5), 449-461.
  • Prime, Schrödinger, 2020, LLC, New York, NY.
  • Kato, A.; Yasuko, H.; Goto, H.; Hollinshead, J.; Nash, R. J.; Adachi, I. Phytomedicine. 2009, 16(2-3), 258-261.
  • Ziegler, D. Nephrol. Dial. Transplant. 2004, 19(9), 2170-2175.
  • Sarfraz, A.; Javeed, M.; Shah, M. A.; Hussain, G.; Shafiq, N.; Sarfraz, I.; Riaz, A.; Sadiqa, A.; Zara, R.; Zafar, S.; Kanwal, L.; Sarker, S.D.; Rasul, A. Sci. Total Environ. 2020, 722, 137907.
  • Alakurtti, S.; Mäkelä, T.; Koskimies, S.; Yli-Kauhaluoma, J. Eur. J. Pharm. Sci. 2006, 29(1), 1-13.
  • Zhou, Y. X.; Xia, W.; Yue, W.; Peng, C.; Rahman, K.; Zhang, H. Evid. Based Complement. Alternat. Med. 2015, 2015, 1-10.

Inhibition profiles and molecular docking studies of antiproliferative agents against aldose reductase enzyme

Yıl 2021, Cilt: 5 Sayı: 1, 77 - 82, 30.06.2021

Namık Kılınç

https://doi.org/10.32571/ijct.944049
Cited By: 3

Öz

Inhibition of Aldose Reductase (AR) is very important in terms of preventing many diabetic complications such as retinopathy, neuropathy, and cataract. In this study, inhibition effects of some antiproliferative agents, which have been shown to have many biological activities besides their anticancer properties, on the AR enzyme, which is a diabetes-related enzyme, were investigated. Biochanin A compound with an IC50 value of 4.44 µM showed the best inhibition effect. IC50 values of Rhein, Betulinic acid, Sanguinarine chloride, Budesonide, Plumbagin and 2-Methoxyestradiol compounds were calculated as 7.87 µM, 7.45 µM, 19.25 µM, 21.00 µM, 28.87 µM and 38.5 µM, respectively. Molecular docking studies have also been conducted to elucidate the inhibition mechanisms of the compounds whose in vitro inhibition effects have been investigated, and the free binding energies of enzyme-inhibitor complexes have been calculated with the Molecular Mechanics Generalized Born Surface Area (MM-GBSA). Both experimental data and computer-aided calculations have revealed that the compounds studied are very important drug candidates aimed at preventing diabetic complications.

Anahtar Kelimeler

Aldose Reductase Antiproliferative Molecular Docking Inhibition

Proje Numarası

2020-SBE-A03

Kaynakça

  • El-Kabbani, O.; Ruiz, F.; Darmanin, C.; Chung, R. T. Cell Mol Life Sci. 2004, 61(7), 750-762.
  • Brownlee, M. Nature. 2001, 414(6865), 813-820.
  • Nishimura, C.; Yamaoka, T.; Mizutani, M.; Yamashita, K.; Akera, T.; Tanimoto, T. Biochim. Biophys. Acta. 1991, 1078(2), 171-178.
  • Hotta, N.; Kawamori, R.; Fukuda, M.; Shigeta, Y. Diabet. Med. 2012, 29(12), 1529-1533.
  • Ramana, K.V.; Srivastava, S.K. Cytokine. 2006, 36, 115-122.
  • Ramasamy, R.; Liu, H.; Oates, P.J.; Schaefer, S. Cardiovasc. Res. 1999, 42, 130-139.
  • Hwang, Y.C.; Sato, S.; Tsai, J.Y.; Yan, S.; Bakr, S.; Zhang, H.; Ramasamy, R. FASEB J. 2002, 16, 243-245.
  • Berry, G.T. Eur. J. Pediatr. 1995, 154, 53-64.
  • Lee, K.W.; Ko, B.C.; Jiang, Z.; Cao, D.; Chung, S.S. Anti-cancer drugs. 2001, 12, 129-132.
  • Regenold, W.T.; Kling, M.A.; Hauser, P. Psychoneuroendocrinology. 2000, 25, 593-606.
  • Regenold, W.T.; Phatak, P.; Kling, M.A.; Hauser, P. Mol. Psychiatry. 2004, 9, 731.
  • Saraswat, M.; Mrudula, T.; Kumar, P.U.; Suneetha, A.; Rao, T.S.; Srinivasulu, M.; Reddy, G.B. Med. Sci. Monit. 2006, 12, 525-529.
  • Ramana, K.V.; Bhatnagar, A.; Srivastava, S.K. FASEB J 2004, 18, 1209–1218.
  • Chandra, D.; Ramana, K.V.; Friedrich, B.; Srivastava, S.; Bhatnagar, A.; Srivastava, S.K. Chem. Biol. Interact. 2003, 143–144, 605–612.
  • Cerelli, K.J.; Curtis, D.L.; Dunn, J.P.; Nelson, P.H.; Peak, T.M.; Waterbury, L.D. J. Med. Chem. 1986, 29, 2347-2351.
  • Schrödinger Release 2020-3: Schrödinger, 2020, LLC, New York, NY.
  • Sastry, G.M.; Adzhigirey, M.; Day, T.; Annabhimoju, R.; Sherman, W. J. Comput. Aided Mol. Des. 2013, 27, 221-234.
  • Friesner, R.A.; Banks, J.L.; Murphy, R.B.; Halgren, T.A.; Klicic, J.J.; Mainz, D.T.; Shenkin, P.S. J. Med. Chem. 2004, 47, 1739-1749.
  • Halgren, T.A.; Murphy, R.B.; Friesner, R.A.; Beard, H.S.; Frye, L.L.; Pollard, W.T.; Banks, J.L. J. Med. Chem. 2004, 47, 1750-1759.
  • Genheden, S.; Ryde, U. Expert. Opin. Drug. Discov. 2015, 10(5), 449-461.
  • Prime, Schrödinger, 2020, LLC, New York, NY.
  • Kato, A.; Yasuko, H.; Goto, H.; Hollinshead, J.; Nash, R. J.; Adachi, I. Phytomedicine. 2009, 16(2-3), 258-261.
  • Ziegler, D. Nephrol. Dial. Transplant. 2004, 19(9), 2170-2175.
  • Sarfraz, A.; Javeed, M.; Shah, M. A.; Hussain, G.; Shafiq, N.; Sarfraz, I.; Riaz, A.; Sadiqa, A.; Zara, R.; Zafar, S.; Kanwal, L.; Sarker, S.D.; Rasul, A. Sci. Total Environ. 2020, 722, 137907.
  • Alakurtti, S.; Mäkelä, T.; Koskimies, S.; Yli-Kauhaluoma, J. Eur. J. Pharm. Sci. 2006, 29(1), 1-13.
  • Zhou, Y. X.; Xia, W.; Yue, W.; Peng, C.; Rahman, K.; Zhang, H. Evid. Based Complement. Alternat. Med. 2015, 2015, 1-10.
Toplam 26 adet kaynakça vardır.

Ayrıntılar

Birincil Dil İngilizce
Konular Kimya Mühendisliği
Bölüm Makale
Yazarlar

Namık Kılınç 0000-0002-9102-1370

Proje Numarası 2020-SBE-A03
Yayımlanma Tarihi 30 Haziran 2021
Yayımlandığı Sayı Yıl 2021 Cilt: 5 Sayı: 1

Kaynak Göster

APA Kılınç, N. (2021). Inhibition profiles and molecular docking studies of antiproliferative agents against aldose reductase enzyme. International Journal of Chemistry and Technology, 5(1), 77-82. https://doi.org/10.32571/ijct.944049
AMA Kılınç N. Inhibition profiles and molecular docking studies of antiproliferative agents against aldose reductase enzyme. Int. J. Chem. Technol. Haziran 2021;5(1):77-82. doi:10.32571/ijct.944049
Chicago Kılınç, Namık. “Inhibition Profiles and Molecular Docking Studies of Antiproliferative Agents Against Aldose Reductase Enzyme”. International Journal of Chemistry and Technology 5, sy. 1 (Haziran 2021): 77-82. https://doi.org/10.32571/ijct.944049.
EndNote Kılınç N (01 Haziran 2021) Inhibition profiles and molecular docking studies of antiproliferative agents against aldose reductase enzyme. International Journal of Chemistry and Technology 5 1 77–82.
IEEE N. Kılınç, “Inhibition profiles and molecular docking studies of antiproliferative agents against aldose reductase enzyme”, Int. J. Chem. Technol., c. 5, sy. 1, ss. 77–82, 2021, doi: 10.32571/ijct.944049.
ISNAD Kılınç, Namık. “Inhibition Profiles and Molecular Docking Studies of Antiproliferative Agents Against Aldose Reductase Enzyme”. International Journal of Chemistry and Technology 5/1 (Haziran 2021), 77-82. https://doi.org/10.32571/ijct.944049.
JAMA Kılınç N. Inhibition profiles and molecular docking studies of antiproliferative agents against aldose reductase enzyme. Int. J. Chem. Technol. 2021;5:77–82.
MLA Kılınç, Namık. “Inhibition Profiles and Molecular Docking Studies of Antiproliferative Agents Against Aldose Reductase Enzyme”. International Journal of Chemistry and Technology, c. 5, sy. 1, 2021, ss. 77-82, doi:10.32571/ijct.944049.
Vancouver Kılınç N. Inhibition profiles and molecular docking studies of antiproliferative agents against aldose reductase enzyme. Int. J. Chem. Technol. 2021;5(1):77-82.

Cited By

Cytotoxic meroterpenoids from brown alga Stypopodium schimperi (Kützing) Verlaque & Boudouresque with comprehensive molecular docking & dynamics and ADME studies
Process Biochemistry
https://doi.org/10.1016/j.procbio.2023.11.029
Resorcinol Derivatives as Novel Aldose Reductase Inhibitors: In Silico and In Vitro Evaluation
Letters in Drug Design & Discovery
https://doi.org/10.2174/1570180819666220414103203
Molecular Mechanisms of Possible Action of Naphthoquinones from Onosma in the Treatment and Prevention of COVID-19
Caucasian Journal of Science
https://doi.org/10.48138/cjo.1037727
 Kapak Resmi İndir

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.